KAI Pharmaceuticals, Inc. Announces Late Breaker Poster Presentation of KAI-4169 Phase 2 Clinical Results at the American Society of Nephrology’s Kidney Week 2011
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced that results from the Company’s Phase 2 study of KAI-4169 will be presented in a late breaker poster presentation at the ongoing annual meeting of the American Society of Nephrology (ASN) on Saturday, November 12, 2011.